Metabolic & Endocrine · Clinical trials
Graves' Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About graves' disease — and why its trials are hard
Graves' disease is an autoimmune disorder in which stimulating antibodies against the TSH receptor drive hyperthyroidism, and it is the most common cause of hyperthyroidism. Features include goiter, weight loss, palpitations, heat intolerance, and, in a subset, Graves' orbitopathy (thyroid eye disease). Three long-established treatments dominate: antithyroid thionamides (methimazole first-line; propylthiouracil reserved for the first trimester of pregnancy and thyroid storm), radioactive iodine (I-131) ablation, and thyroidectomy. Methimazole restores euthyroidism in most patients within weeks, with roughly half achieving lasting remission after a 12-18 month course; the remainder relapse and often proceed to definitive therapy. These agents predate modern randomized-trial approval frameworks, so their approvals rest on decades of clinical use rather than contemporary pivotal endpoints. Importantly, teprotumumab (Tepezza, 2020) is approved for thyroid eye disease, a Graves' manifestation, and not for hyperthyroidism itself. No disease-modifying immunotherapy has yet been approved for the underlying autoimmunity, and antibody-directed and antigen-specific approaches remain investigational, marking a clear unmet need.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Methimazole (Tapazole) | 1950 (historical) | First-line antithyroid thionamide | Historical approval predating modern pivotal-trial requirements | Restoration of euthyroidism (normalization of thyroid hormones) | Euthyroid in most patients within 3-6 weeks; ~50% durable remission after a 12-18 month course |
| Propylthiouracil (PTU) ((generic)) | 1947 (historical) | Second-line thionamide; preferred in first-trimester pregnancy and thyroid storm | Historical approval predating modern pivotal-trial requirements | Normalization of thyroid hormone levels | Effective control comparable to methimazole; carries higher hepatotoxicity risk (black-box warning) |
| Sodium iodide I-131 (radioactive iodine) ((generic I-131)) | ~1951 (historical) | Definitive ablative therapy for hyperthyroidism | Historical approval; long-standing clinical evidence base | Control of hyperthyroidism (frequently via induced hypothyroidism) | High rates of durable cure; most patients ultimately require lifelong levothyroxine |
| Teprotumumab (Tepezza) | 2020 | IGF-1 receptor antagonist for thyroid eye disease (a Graves' manifestation), NOT for hyperthyroidism itself | OPTIC (Phase III, NEJM 2020) | Proptosis responder rate (≥2 mm reduction) at week 24 | 83% responders vs 10% placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in graves' disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Rituximab (anti-CD20) — Off-label/investigational studies in Graves' hyperthyroidism | Mixed and inconsistent effects on hyperthyroidism; never established as an approved therapy for Graves' | Variable and modest efficacy, infusion/immunosuppression risks, and no adequately powered pivotal program (magnitude unverified) |
| Iscalimab (CFZ533, anti-CD40) — Phase II in Graves' disease | Did not deliver sufficient durable control of hyperthyroidism to advance to registration | Insufficient/short-lived efficacy signal in the target population (magnitude unverified) |
Choosing the right endpoint
Primary endpoints that matter in graves' disease trials
- Serum free T4 and total T3 — Core markers of hyperthyroidism control and titration of antithyroid drugs
- TSH normalization — Often lags behind free hormones; used to confirm sustained euthyroidism
- TSH-receptor antibody (TRAb) titers — Reflect autoimmune activity; falling titers predict remission likelihood
- Remission/relapse after drug withdrawal — Key long-term efficacy measure after a defined thionamide course
- Proptosis response (for thyroid eye disease) — Teprotumumab OPTIC endpoint (≥2 mm proptosis reduction); specific to the ocular manifestation
How iNGENū runs graves' disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Graves' Disease clinical trials — FAQs
Is teprotumumab a treatment for Graves' disease?
Which antithyroid drug is preferred?
Can Graves' disease be cured?
Ready to discuss your graves' disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal